UNSPSC 51122500: Combination antiarrhythmics

This classification denotes combination preparations for the treatment or prevention of disturbances of the normal rhythmic beating of the heart. they may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Typical combination antiarrhythmic constituients are bretylium, dextrose, and lidocaine.

UNSPSC 51122500 Combination antiarrhythmics is a Class code covering individual cardiac medications used in emergency medical services and broader healthcare procurement. State and local governments purchase these drugs primarily for emergency response systems and institutional pharmacy programs, as evidenced by solicitations from fire rescue departments and state health agencies. The City of Tampa's recent procurement (Bid No. 26-P-00188) demonstrates the core scope: sealed-bid sourcing of specific Advanced Life Support medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products shows the broader institutional context in which combination antiarrhythmics sit alongside other therapeutic categories. Issuing bodies include city purchasing departments, state health and human services commissions, and multistate cooperative purchasing vehicles; fire rescue departments and state pharmacy benefit programs are the primary end users.

Recent activity spans Florida and Texas, with multistate purchasing leverage through MMCAP touching Minnesota and Oregon. The City of Tampa issued an IFB (Bid No. 26-P-00188, due April 8, 2026) with an estimated contract value of $40,000 and a one-year term plus two optional renewals, including a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted an RFI (No. HHS0017013, April 3, 2026) to assess vendor capabilities for direct-to-manufacturer prescription programs as a preliminary market-research step. MMCAP's RFP (S1070000015802, due March 26, 2026) called for generic multi-source pharmaceuticals through authorized wholesalers with a July 1, 2026 effective date, emphasizing price competitiveness (75 percent weight), cGMP and DSCSA compliance, and insurance requirements including $5,000,000 commercial general liability. The Tampa solicitation requires nine-month minimum expiration dates, ten-day delivery, and OSHA Safety Data Sheets; MMCAP requires one-year minimum shelf life with six-month usable life and FDA compliance. Both demonstrate the operational and regulatory rigor expected in state and local pharmaceutical sourcing.